ECOLCOVID: Ventilation Associated Pneumonia and Covid-19
Study Details
Study Description
Brief Summary
In December 2019, a new pandemic emerged, the COVID-19 disease caused by a SARS-Cov-2 virus. One of the most common symptoms of COVID-19 is mainly respiratory failure and patients requires assistance by mechanical ventilation. Ventilator-associated pneumonia (VAP) is a risk of this assistance. Since the beginning of the pandemic, Standard of care have evolved with new data. The prevalence of these VAPs seems significantly higher in the population of patients with ARDS COVID-19 (40-50%) and their ecology seems to have evolved over time, particularly in terms of bacterial resistance. Investigators want to describe and compare this evolution of bacterial and fungal ecology as well as identify potential risk factors that may be associated with these changes in ecology during different waves.
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
|
Study Design
Arms and Interventions
Arm | Intervention/Treatment |
---|---|
Patient from the first wave of COVID-19 57 Patients hospitalized in intensive care unit for pneumonia related to a Sars-Cov2 infection who required mechanical ventilatory support and developed microbiologically documented ventilator associated pneumonia during the 1st wave from January 24, 2020 to July 10, 2020 |
|
Patient from the Second wave of COVID-19 211 Patients hospitalized in intensive care unit for pneumonia related to a Sars-Cov2 infection who required mechanical ventilatory support and developed microbiologically documented ventilator associated pneumonia during the 2nd wave from July 11, 2020 to January 8, 2021 |
Outcome Measures
Primary Outcome Measures
- VAP ecological difference between the first and second waves of COVID [January 2020 to January 2021]
Proportion of patients admitted to critical care with documented multidrug-resistant bacteria (MDR) VAP in Covid-19 wave 1 and 2
Secondary Outcome Measures
- proportion of fungal co-infections [January 2020 to January 2021]
Comparison of the proportion of patients with a fungal infection during the 1st and 2nd wave
- duration of mechanical ventilation [Day 28]
Number of days under mechanical ventilations
- number of days of organ failure [Day 28]
number of days between first organ failure and no organ failure (discharge from intensive care)
- Mortality [Day 28]
proportion of patients deceased at day 28
- proportion of patients treated with corticosteroid therapy [Day 28]
proportion of patients treated with corticosteroid therapy
- probabilistic antibiotic therapy at admission [Day 1]
probabilistic antibiotic therapy prescribed at admission
- antiviral treatment [Day 28]
proportion of patients treated with antiviral treatment
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Age > 18 years
-
Positive SARS-Cov-2 polymerase chain reaction (PCR)
-
healthcare associated pneumonia
Exclusion Criteria : Patient opposition to participate to the study
Contacts and Locations
Locations
Site | City | State | Country | Postal Code | |
---|---|---|---|---|---|
1 | CHU de Nîmes - Hôpital Universitaire Carémeau | Nîmes Cedex 09 | France | 30029 |
Sponsors and Collaborators
- Centre Hospitalier Universitaire de Nīmes
Investigators
- Principal Investigator: Claire ROGER, MD, PhD, Centre Hospitalier Universitaire de Nîmes
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- LOCAL/2021/LC-01